Ankyra Therapeutics
Austin, US · Founded 2019 · 1 known investors
Ankyr develops a localized immunotherapy platform that anchors immune-modulating drugs at tumor sites using aluminum hydroxide, designed to improve efficacy and reduce systemic side effects in cancer treatment. The company's lead program ANK-101, an anchored IL-12 therapy, is in clinical evaluation for advanced solid tumors.
Founders & leadership
TM
Terrance McGuireDirector
TG
Tillman GerngrossExecutive Officer, Director
Investors · 1
Reported raises · per SEC filings
Form D private placements$45MraisedSep 2021 · 14 investors · Biotechnology
Rule 506(b)$14.5MraisedMay 2020 · 4 investors · Other Health Care
Rule 506(b)Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.